DLL4 and pulmonary arterial hypertension: DLL4/NOTCH1/N1ICD was also found to interact with and target PPARγ, a BMPR2 downstream effector (19) that has anti-inflammatory and anti-proliferative functions in the vasculature (46) and has been described to guard against the development of PAH (18).